Business Wire
Alnylam Pharmaceuticals Announces Changes to Board of Directors
📊
AI Sentiment
Positive
7/10
- Home
- ALNY
as of 12-03-2025 3:41pm EST
$472.35
+$7.42
+1.59%
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Chart Type:
Time Range:
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 60.1B | IPO Year: | 2004 |
| Target Price: | $483.89 | AVG Volume (30 days): | 931.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 27 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $205.87 - $495.55 | Next Earning Date: | 10-30-2025 |
| Revenue: | $3,210,070,000 | Revenue Growth: | 53.24% |
| Revenue Growth (this year): | 65.55% | Revenue Growth (next year): | 41.48% |
AI-Powered ALNY Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 70.75%
70.75%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Alnylam Pharmaceuticals Inc. (ALNY)
Fitzgerald Kevin Joseph
Sell
CSO & EVP, Head of Research
ALNY Nov 17, 2025
Avg Cost/Share
$456.70
Shares
12,128
Total Value
$5,483,989.61
Owned After
25,224
Greenstreet Yvonne
Sell
Chief Executive Officer
ALNY Nov 13, 2025
Avg Cost/Share
$451.86
Shares
10,000
Total Value
$4,512,681.86
Owned After
68,345
Greenstreet Yvonne
Sell
Chief Executive Officer
ALNY Nov 12, 2025
Avg Cost/Share
$453.42
Shares
15,650
Total Value
$7,100,321.56
Owned After
68,345
Garg Pushkal
Sell
EVP Chief R&D
ALNY Oct 3, 2025
Avg Cost/Share
$452.05
Shares
3,022
Total Value
$1,364,387.18
Owned After
20,221
Fitzgerald Kevin Joseph
Sell
CSO & EVP, Head of Research
ALNY Oct 2, 2025
Avg Cost/Share
$452.32
Shares
2,441
Total Value
$1,103,451.46
Owned After
25,224
Greenstreet Yvonne
Sell
Chief Executive Officer
ALNY Oct 2, 2025
Avg Cost/Share
$452.32
Shares
8,924
Total Value
$4,034,084.66
Owned After
68,345
Garg Pushkal
Sell
EVP Chief R&D
ALNY Oct 2, 2025
Avg Cost/Share
$452.32
Shares
2,937
Total Value
$1,327,674.71
Owned After
20,221
Tanguler Tolga
Sell
EVP, Chief Commercial Officer
ALNY Oct 2, 2025
Avg Cost/Share
$452.32
Shares
1,405
Total Value
$635,126.28
Owned After
28,788
Poulton Jeffrey V.
Sell
EVP, Chief Financial Officer
ALNY Oct 2, 2025
Avg Cost/Share
$452.32
Shares
3,821
Total Value
$1,727,283.60
Owned After
57,650
Reitan Colleen F
Sell
Director
ALNY Sep 9, 2025
Avg Cost/Share
$469.51
Shares
18,000
Total Value
$8,416,729.64
Owned After
9,424
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Fitzgerald Kevin Joseph | ALNY | CSO & EVP, Head of Research | Nov 17, 2025 | Sell | $456.70 | 12,128 | $5,483,989.61 | 25,224 | |
| Greenstreet Yvonne | ALNY | Chief Executive Officer | Nov 13, 2025 | Sell | $451.86 | 10,000 | $4,512,681.86 | 68,345 | |
| Greenstreet Yvonne | ALNY | Chief Executive Officer | Nov 12, 2025 | Sell | $453.42 | 15,650 | $7,100,321.56 | 68,345 | |
| Garg Pushkal | ALNY | EVP Chief R&D | Oct 3, 2025 | Sell | $452.05 | 3,022 | $1,364,387.18 | 20,221 | |
| Fitzgerald Kevin Joseph | ALNY | CSO & EVP, Head of Research | Oct 2, 2025 | Sell | $452.32 | 2,441 | $1,103,451.46 | 25,224 | |
| Greenstreet Yvonne | ALNY | Chief Executive Officer | Oct 2, 2025 | Sell | $452.32 | 8,924 | $4,034,084.66 | 68,345 | |
| Garg Pushkal | ALNY | EVP Chief R&D | Oct 2, 2025 | Sell | $452.32 | 2,937 | $1,327,674.71 | 20,221 | |
| Tanguler Tolga | ALNY | EVP, Chief Commercial Officer | Oct 2, 2025 | Sell | $452.32 | 1,405 | $635,126.28 | 28,788 | |
| Poulton Jeffrey V. | ALNY | EVP, Chief Financial Officer | Oct 2, 2025 | Sell | $452.32 | 3,821 | $1,727,283.60 | 57,650 | |
| Reitan Colleen F | ALNY | Director | Sep 9, 2025 | Sell | $469.51 | 18,000 | $8,416,729.64 | 9,424 |
Latest Alnylam Pharmaceuticals Inc. News
ALNY Breaking Stock News: Dive into ALNY Ticker-Specific Updates for Smart Investing
Investor's Business Daily
How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint
📊
AI Sentiment
Positive
7/10
Simply Wall St.
Spotlight On Alnylam Pharmaceuticals And 2 Other Stocks Possibly Trading Below Fair Value
📈
AI Sentiment
Highly Positive
8/10
GlobeNewswire
KINGSONG Launches Four Next-Generation Electric Unicycles, Setting a New Benchmark for Intelligent Mobility
📈
AI Sentiment
Highly Positive
9/10
24/7 Wall St.
XRP Price Target December 2025: ChatGPT AI Predicts $2.02 vs Analysts’ $2.85
➖
AI Sentiment
Neutral
4/10
CNW Group
Various pistachios and pistachio-containing products recalled due to Salmonella
📉
AI Sentiment
Negative
3/10
Pioneer Press, St. Paul, Minn.
Small Business Saturday spotlight: New women’s boutique on Grand Avenue
📊
AI Sentiment
Positive
7/10
Compare ALNY vs Leading Stocks
See how ALNY stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ALNY Alnylam Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.